Market leadership MVE Biological Solutions is a global leader in cryogenic storage and shipping devices with a 60-year track record, indicating reliability and a strong brand that can be leveraged to win contracts in biopharma, cell and gene therapy, IVF, and hospital settings.

Acquisition context Cryoport’s 2020 acquisition of MVE signals strategic consolidation in cryogenic logistics, suggesting cross-sell opportunities with Cryoport’s cold chain services and expanded distribution channels to reach new customers.

Financial potential With estimated revenue in the mid-ten millions, there is room for growth through expanded product lines, bundled solutions, and premium service offerings to capture larger accounts in biopharma, research facilities, and government institutions.

Product awards ISBER award recognition for MVE Fusion highlights innovation and quality, providing sales leverage when targeting labs and procurement teams that prioritize validated, award-winning equipment for compliance and reliability.

Customer fit A broad installed base across biopharma, cord blood and stem cell storage, IVF centers, hospitals, and government facilities presents opportunities for upsell of complementary storage, shipping, and monitoring solutions, as well as expansion into adjacent end-markets like livestock and animal husbandry.